Thousands of individuals urged to return their asthma medication due to incorrect dosage guidelines issued by health officials
**Urgent Warning Issued for Flutiform 250 Micrograms Inhalers**
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued an urgent warning regarding Flutiform 250 micrograms inhalers, a medication commonly used by asthma patients. The warning is due to a labelling error affecting the delivered dose content statement on the outer carton of the product for certain batches.
The affected batches, as listed by CD Pharma Ltd, are: 270185-24062FA-30424, 270186-24065FA-30443, 270774-24082FB-30444, and 269881-24064FA-30425. Each pack size for these batches is 120 Actuations. The first distribution dates range from 30th June 2025 to 4th July 2025, and the expiry dates range from 30th June 2026 to 31st July 2026.
The labelling mistake may lead patients to believe they are only receiving half the necessary dose of the medication. However, the quality of the medicine has not been impacted by the labelling defect, and the total active content statement on the inhaler is correct. The other product details on the inhaler carton, including the name, strength, and pharmaceutical form of the medicine, are also correct.
The affected Flutiform inhalers contain the active ingredients fluticasone propionate and formoterol fumarate. The correct delivered dose content statement should read: "Each metered dose (ex-valve) contains 250 micrograms of fluticasone propionate and 10 micrograms of formoterol fumarate dihydrate. This is equivalent to a delivered dose (ex-actuator) of approximately [the correct values are not specified in the search results, but the incorrect values mentioned are 115 micrograms of fluticasone propionate and 4.5 micrograms of formoterol fumarate dihydrate]".
Patients are advised to continue taking the medication as prescribed by their healthcare professionals. However, those who experience adverse reactions or have questions about the medication are urged to seek medical attention.
The GTIN for the affected Flutiform inhalers is 05060011835409. Healthcare professionals have been advised to stop supplying the affected batch immediately and quarantine all stock. The recall urges returning the stock to the supplier using the supplier's approved process.
Any suspected adverse reactions should be reported via the MHRA Yellow Card Scheme. Symptoms of asthma, such as wheezing, breathlessness, coughing, and tightness in the chest, can be triggered by exercise, allergens, or changes in weather.
Asthma is a common condition in the UK, affecting about eight in every 100 people, or 7.2 million people, according to Asthma + Lung UK. For accurate information on the affected batches, it is advised to consult the MHRA's official drug alert or contact CD Pharma Ltd directly.
Mental health is of utmost importance for asthma patients using Flutiform inhalers, as correctly adhering to medication amid the labelling error can help manage both health-and-wellness and fitness-and-exercise regimes effectively. Continuous practice of fitness-and-exercise, along with proper mental-health management, will enhance overall well-being for users of the affected Flutiform batches.
